The Nevada Athletic Commission has instituted new policies that draw the line between what drug testing results it deems “atypical” as opposed to “adverse.” At a monthly meeting Tuesday, the NAC established new thresholds for substances previously prohibited: GW1516, dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3), clomiphene, epitrenbolone (trenbolone metabolite), and selective androgen receptor modulators (SARMS). The official proposal voted on and approved is as follows, according to NAC executive director Jeff Mullen: “Any positive test of a proposed substance, which is below the respective proposed threshold, would be considered atypical requiring additional investigation. This investigation may include, but not be limited to, review of the fighter’s test history, interviews, and possible additional testing. The results will remain atypical absent evidence that would negate the presence of mitigation associated with the below-threshold amount. If additional evidence eliminated mitigating circumstances, the case would proceed through standard disciplinary proceedings. These disciplinary proceedings would include the filing of a formal disciplinary complaint, as well as the possible issuance of a temporary suspension.” The following thresholds for each substance have been instituted, according to an exhibit document acquired by MMA Junkie.
See the article here: